Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension
JACC · 2026-05 · 87 (18) · 2508-2520
DOI: 10.1016/j.jacc.2026.03.034 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2026-05. Verfasst von Luke J Laffin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA; Clevel…. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Oligonucleotides, Antisense, Oligonucleotides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
BACKGROUND: Angiotensinogen production represents the rate-limiting step in activation of the renin-angiotensin-aldosterone system. Tonlamarsen is an investigational antisense oligonucleotide directed against hepatic angiotensinogen synthesis; its efficacy and safety among patients with hypertension are unknown. OBJECTIVES: The aim of this study was to assess the safety and efficacy of 90 mg tonlamarsen administered subcutaneously once monthly for 5 months compared with a single dose of tonlamarsen and subsequent placebo. METHODS: This randomized, placebo-controlled trial enrolled adults with office systolic blood pressure (BP) >135 mm Hg receiving 2 to 5 antihypertensive medications. Participants entered a 3-part treatment period with monthly administration of the study drug, consisting of a 4-week placebo lead-in, followed by 4-week active run-in with a single dose of tonlamarsen and subsequent randomization to 4 additional doses of tonlamarsen or matching placebo for 16 weeks. The coprimary endpoints were the between-group differences in the change from baseline to week 20 in plasma angiotensinogen and in office systolic BP. RESULTS: A total of 279 participants received placebo lead-in, 206 received 90 mg tonlamarsen during the active run-in, and 198 were randomized. The mean BP among randomized participants before and after the placebo lead-in was 147/90 and 147/89 mm Hg, respectively. Following active run-in with tonlamarsen, the mean BP was 140/87 mm Hg. Twenty weeks following the first dose of tonlamarsen, least squares (LS) mean percentage changes in plasma angiotensinogen levels were -23.0% (95% CI: -27.8% to -18.2%) with a single dose of tonlamarsen and subsequent placebo and -67.2% (95% CI: -71.9% to -62.4%) with monthly tonlamarsen administration, with a LS mean difference of -44.1% (97.5% CI: -51.9% to -36.4%; P < 0.0001). The LS mean changes in office systolic BP were -6.7 mm Hg (95% CI: -9.8 to -3.5 mm Hg) for participants following a single dose of tonlamarsen and subsequent placebo and -6.7 mm Hg (95% CI: -9.8 to -3.6 mm Hg) for participants treated with monthly tonlamarsen, with a LS mean difference of -0.1 mm Hg (95% CI: -4.5 to -4.4 mm Hg; P = 0.97). Serious adverse events were infrequent and similar between treatment groups. CONCLUSIONS: Among individuals with uncontrolled hypertension, monthly tonlamarsen administration was more effective at lowering plasma angiotensinogen compared with a single tonlamarsen dose, but there was no additional BP reduction. (A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension [KARDINAL]; NCT06864104).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA; Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio,…
- Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio, USA.
- Research Institute of the McGill University Health Centre, McGill University, Montréal, Québec, Canada.
- Dobney Hypertension Centre, Medical School-Royal Perth Hospital Research Foundation, University of Western Australia, Perth, Western Australia, Australia.
- Department of Medicine, Renal Division University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Clinic of Cardiology, University Heart Center, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Heart Center, University Hospital Basel, Basel, Switzerland.
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Laffin, L. J., Wang, Q., Sarraju, A., Touyz, R. M., Schlaich, M. P., Cohen, D. L., Mahfoud, F., Mitchell, L. M., Mitchell, J., Wolski, K., Dennis, P., Akere, A., Li, W., Chen, G., Cohen, Y. Z., Kim, J., Cooper, C. G., Ramesan, P., Edelberg, J. M., …, & KARDINAL Investigators (2026). Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension. JACC, 87(18), 2508-2520. https://doi.org/10.1016/j.jacc.2026.03.034
Vancouver
Laffin LJ, Wang Q, Sarraju A, Touyz RM, Schlaich MP, Cohen DL, et al. Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension. JACC. 2026;87(18):2508-2520. doi:10.1016/j.jacc.2026.03.034
BibTeX
@article{Laffin2026,
author = {Laffin, Luke J and Wang, Qiuqing and Sarraju, Ashish and Touyz, Rhian M and Schlaich, Markus P and Cohen, Debbie L and Mahfoud, Felix and Mitchell, Lisa M and Mitchell, Jennifer and Wolski, Kathy and Dennis, Patrick and Akere, Ayoade and Li, Wanying and Chen, Gene and Cohen, Yehuda Z and Kim, Jessica and Cooper, Caroline G and Ramesan, Prameela and Edelberg, Jay M and Nissen, Steven E and KARDINAL Investigators, KARDINAL Investigators},
title = {Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension},
journal = {JACC},
year = {2026},
volume = {87},
number = {18},
pages = {2508--2520},
doi = {10.1016/j.jacc.2026.03.034}
}
EUVIMED